Welcome to our dedicated page for Beyond Air news (Ticker: XAIR), a resource for investors and traders seeking the latest updates and insights on Beyond Air stock.
Beyond Air Inc (NASDAQ: XAIR) is a clinical-stage medical technology company pioneering nitric oxide delivery systems for respiratory care. This news hub provides investors and healthcare professionals with essential updates on regulatory milestones, clinical trial progress, and technological advancements related to the LungFit™ platform.
Access timely press releases covering FDA communications, partnership announcements, and research developments in pulmonary hypertension treatment. Our curated collection includes updates on international regulatory strategies and peer-reviewed study publications, offering critical insights into the company's position within the respiratory therapy market.
Key content categories include clinical trial results, device approval updates, executive leadership changes, and scientific conference presentations. This resource enables stakeholders to track the company's progress in developing NO-based solutions for ventilator-associated pneumonia and chronic lung conditions.
Bookmark this page for streamlined access to material developments affecting XAIR's market position. For comprehensive analysis of how these updates may influence investment decisions, consult your financial advisor and review official SEC filings.
Beyond Air (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company focused on nitric oxide (NO) treatments, has scheduled its fiscal Q2 2025 financial results conference call for November 11, 2024, after market close. The earnings call will be held at 4:30 PM ET, accessible via phone (domestic: 1-877-407-0784; international: 1-201-689-8560) and webcast through the company's website. A replay will be available online after the call.
Beyond Cancer, , a clinical stage biotechnology company, has been selected to present two poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024. The event is scheduled for November 6-10 at the George R. Brown Convention Center in Houston, Texas. The company will showcase preclinical data on their ultra-high concentration nitric oxide (UNO) Low Volume Therapy.
The presentations will focus on the intratumoral administration of low volume high-concentration nitric oxide in combination with immune checkpoint inhibitors in different tumor models. The studies demonstrated therapeutic efficacy in both mice and rat tumor models. Abstracts will be released to SITC registrants on November 5, 2024, at 9:00 AM U.S. ET, while the full poster presentations will take place on November 8th and 9th. ePublications of the posters will be available on the company's website on November 7th.
Beyond Air (NASDAQ: XAIR) has announced a strategic partnership with Healthcare Links to expand access to its LungFit® PH system through Group Purchasing Organizations (GPOs) and Integrated Delivery Networks (IDNs) across the United States. The LungFit® PH system is a groundbreaking inhaled nitric oxide (NO) generator and delivery system for treating persistent pulmonary hypertension of the newborn (PPHN) and other respiratory conditions.
This partnership aims to streamline the entry of Beyond Air's technology into healthcare systems, leveraging Healthcare Links' expertise in facilitating relationships with GPOs and IDNs. The LungFit® PH system generates NO on-demand from ambient air, eliminating cylinder storage needs and enhancing patient safety and operational efficiency. The collaboration is expected to fast-track the availability of LungFit PH to a larger network of hospitals and healthcare providers, potentially benefiting more patients, particularly vulnerable newborns.
Beyond Air, Inc. (NASDAQ: XAIR) has deployed its LungFit® PH system to the U.S. Naval Hospital Guam for neonatal critical care, in partnership with TrillaMed. The LungFit® PH system generates Nitric Oxide (NO) from room air to treat persistent pulmonary hypertension in neonates (PPHN). Key features include a portable design, advanced NO generating technology, and easy integration into hospital infrastructure.
The U.S. Naval Hospital Guam serves over 17,000 active-duty military personnel and family members, with an expected increase of 2,500 in the next two years. The hospital currently delivers an average of 315 babies per year, projected to rise to 487 births by 2033. This deployment demonstrates the hospital's commitment to utilizing advanced technologies in neonatal care for military families.
Beyond Air (NASDAQ: XAIR) has announced significant financial restructuring, terminating its loan agreements with Avenue Capital and entering a new $11.5 million loan agreement with an insider-led investor group. The company is retiring $17.5 million in Avenue Capital debt, eliminating $12 million in scheduled debt payments through June 2026. The new loan agreement defers payment of principal and interest until June 2026.
Notably, Beyond Air reports a 60% increase in hospital contracts since July 1, 2024, including a contract with U.S. Naval Hospital Guam. The company's CEO, Steve Lisi, emphasized that these transactions strengthen the balance sheet, extend cash runway, and support commercial momentum for LungFit PH. David Webster, Chief Commercial Officer, expressed confidence in LungFit PH's potential to gain significant market share in the United States and globally.
The company is withdrawing its previous revenue guidance for fiscal year 2025 but believes the financial restructuring will provide sufficient cash runway through June 2026.
Beyond Air (NASDAQ: XAIR) has announced a $20.6 million private placement offering priced at-the-market under Nasdaq rules. The company is selling 40,392,155 shares of common stock (or pre-funded warrants) and accompanying warrants at $0.51 per share. This financing is expected to provide sufficient cash runway through June 2026.
Additionally, Beyond Air is retiring $17.5 million in Avenue Capital debt, aided by $11.5 million in new debt from an insider-led group. This eliminates $12 million in scheduled debt payments through June 2026. The company has also entered into an $11.5 million royalty funding agreement based on net sales of LungFit PH.
The private placement is expected to close around September 30, 2024, subject to certain conditions. BTIG, acted as the lead placement agent, with Laidlaw & Company, JonesTrading, and Brookline Capital Markets as co-placement agents.
Beyond Air, Inc. (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, has announced its participation in the 3rd Annual ROTH Healthcare Opportunities Conference. The event will take place on October 9th at the Metropolitan Club in New York.
Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will be available for one-on-one meetings during the conference. Interested parties are encouraged to contact their ROTH representative to schedule a meeting. This participation provides an opportunity for Beyond Air to engage with potential investors and industry professionals, showcasing their innovative work in nitric oxide-based medical solutions.
Beyond Air (NASDAQ: XAIR) reported fiscal Q1 2025 results, showing a 45% revenue increase compared to the previous quarter. The company reiterated its FY 2025 revenue guidance of at least $10 million. Key highlights include:
- LungFit PH commercial execution strengthening, with devices used in over 55 hospitals across 10 U.S. states
- More than $7 million in aggregate contracted revenue through FY 2027
- Amir Avniel appointed CEO of NeuroNOS, focusing on neurological disorders
- Implemented capital conservation strategy, reducing headcount by over 25% since January 2024
- Q1 FY2025 revenue: $0.7 million; Net loss: ($12.2) million or ($0.27) per share
- Cash position: $21.4 million as of June 30, 2024
Beyond Air (NASDAQ: XAIR) has published a peer-reviewed article in Scientific Reports, demonstrating the safety and benefits of nitric oxide (NO) as an adjunct therapy for viral pneumonia. The study, conducted on COVID-19 patients, showed that 150-ppm intermittent inhaled NO administered with the LungFit® PRO device was well-tolerated and beneficial compared to usual care. Key findings include:
1. Mitigation of viral pneumonia severity
2. Enhanced recovery with reduced time to reach stable room air saturation
3. Shortened duration of supportive oxygen need
The company views these results as promising for further investigation of inhaled NO in treating viral and bacterial lung infections. Beyond Air is currently focusing on commercializing LungFit PH for treating term and near-term neonates with hypoxic respiratory failure.
Beyond Air (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company, has announced it will report its first fiscal quarter 2025 financial results on Tuesday, August 6, 2024, after the market closes. The company focuses on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors (through its affiliate Beyond Cancer, ). The financial results will cover the period ended June 30, 2024.
FAQ
What is the current stock price of Beyond Air (XAIR)?
What is the market cap of Beyond Air (XAIR)?
